Catalent (CTLT)
(Delayed Data from NYSE)
$59.95 USD
+1.47 (2.51%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $59.92 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.95 USD
+1.47 (2.51%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $59.92 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
Earnings Preview: Catalent (CTLT) Q3 Earnings Expected to Decline
by Zacks Equity Research
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalent (CTLT) Declines on Profit Warnings and CFO Exit
by Zacks Equity Research
Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
by Zacks Equity Research
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses
by Zacks Equity Research
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
by Zacks Equity Research
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
Zoetis (ZTS) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
Compared to Estimates, Catalent (CTLT) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Catalent (CTLT) Surges on Rumors of Acquisition by Danaher
by Zacks Equity Research
Catalent (CTLT) shares gain significantly, following a Bloomberg report about a potential acquisition of the CDMO company by Danaher, a life sciences company.
Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.
Catalent (CTLT) Misses Q2 Earnings Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -6.94% and 2.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Catalent (CTLT)
by Zacks Equity Research
Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.
Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology
by Zacks Equity Research
Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Why Is Jazz (JAZZ) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalent (CTLT) Expands Facility Capabilities in Shanghai
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.
Why Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day.